BMC research notes
-
Multicenter Study Observational Study
Perioperative patient safety indicators and hospital surgical volumes.
Since the late 1990s, patient safety has been an important policy issue in developed countries. To evaluate the effectiveness of the activities of patient safety, it is necessary to quantitatively assess the incidence of adverse events by types of failure mode using tangible data. The purpose of this study is to calculate patient safety indicators (PSIs) using the Japanese Diagnosis Procedure Combination/per-diem payment system (DPC/PDPS) reimbursement data and to elucidate the relationship between perioperative PSIs and hospital surgical volume. ⋯ We demonstrated that PSIs can be calculated using DPC/PDPS data and perioperative PSIs were related to hospital surgical volume. Further investigations focusing on identifying risk factors for poor PSIs and effective support to these hospitals are needed.
-
Clinical Trial
Agent consumption with the Zeus® in the automated closed circuit anesthesia mode with O2/air mixtures.
Earlier software versions of the Zeus® (Lübeck, Dräger, Germany) failed to provide true closed circuit anesthesia (CCA) conditions. We examined whether the latest software (SW 4.03 MK 04672-00) achieves this goal. ⋯ Under the conditions specified, the Zeus® approaches CCA conditions so closely that further reductions in agent usage would have minimal economic significance.
-
This post hoc analysis assessed the safety, tolerability and effectiveness of long-term treatment with aripiprazole adjunctive to either bupropion or selective serotonin reuptake inhibitors (SSRIs)/serotonin-norepinephrine reuptake inhibitors (SNRIs) in patients with major depressive disorder (MDD). ⋯ There were no unexpected AEs with long-term adjunctive aripiprazole therapy when added to either bupropion or SSRIs/SNRIs, and symptom improvement was similar between ADT groups. Sexual functioning in patients with MDD on antidepressants was also modestly improved after adding aripiprazole.
-
There is a lack of an instrument to evaluate systematic reviews of non-randomized studies in epidemiological research. The Assessment of Multiple Systematic Reviews (AMSTAR) is widely used to evaluate the scientific quality of systematic reviews, but it has not been validated for SRs of non-randomized studies. The objective of this paper is to report our experience in applying AMSTAR to systematic reviews of non-randomized studies in terms of applicability, reliability and feasibility. Thus, we applied AMSTAR to a recently published review of 32 systematic reviews of non-randomized studies investigating the hospital volume-outcome relationship in surgery. ⋯ AMSTAR showed good psychometric properties, comparable to prior findings in systematic reviews of randomized controlled trials. AMSTAR can be applied to systematic reviews of non-randomized studies, although there are some item specific issues users should be aware of. Revisions and extensions of AMSTAR might be helpful.
-
The AS04-adjuvanted bivalent L1 virus-like-particle (VLP) vaccine (Cervarix™) against infection with human papillomavirus (HPV) types 16/18 holds great promise to prevent HPV16/18 infections and associated neoplasias, but it is important to rule out significant co-factors of the neoplasias like smoking. ⋯ Our data suggest that while smoking does not interfere with the quantity of vaccine-induced peak IgG levels, it may affect the avidity of IgG induced by HPV16/18 vaccination.